Drug Safety

, Volume 32, Issue 7, pp 591–597 | Cite as

Statins and Erectile Dysfunction

Results of a Case/Non-Case Study using the French Pharmacovigilance System Database
  • Catherine Do
  • Eric Huyghe
  • Maryse Lapeyre-Mestre
  • Jean Louis Montastruc
  • Haleh BagheriEmail author
Original Research Article


Background: HMG-CoA reductase inhibitors, more commonly called statins, are widely used in the pharmacological management of hyperlipidaemias. The most common adverse drug reactions (ADRs) of statins are muscular. Other reported ADRs of statins along with other lipid-lowering drugs, namely fibrates, include erectile dysfunction (ED). The relationship between ED and exposure to statins has not clearly been established even though a number of significant case reports have associated ED with exposure to statins.

Objective: To investigate the association between exposure to statins and the occurrence of ED on the French Pharmacovigilance System Database.

Methods: Within the French Pharmacovigilance System Database, the case/ non-case method was used to measure the disproportionality of combination between a statin and ED. Cases are defined as those reports corresponding to the ADR of interest (i.e. ED) and non-cases are all reports of ADRs other than that being studied. The study period was from 1 January 1985 to 31 December 2006, limited to males aged 13–80 years. We estimated the association between ED and statins by calculating a reporting odds ratio (ROR) of exposure to each drug, with its 95% confidence interval (CI).

Results: Among the total of spontaneous reports selected (110 685), exposure to statins was identified in 4471 cases (4%), of which 51 reports (1.1%) concerned ED, whereas 431 (0.4%) cases of ED were found in the 106 214 reports without exposure to statins (p< 0.0001). The mean delay of onset of ED after starting statins, known for 19 cases, was 62 days (median 29 days). In 56.9% of cases, recovery occurred after withdrawal of statin, and rechallenge was positive in five cases.

The association was statistically significant for all statins (adjusted ROR [aROR] = 2.4; 95% CI 1.8, 3.3), simvastatin (aROR = 2.6; 1.6, 4.1), atorvastatin (aROR=3.4; 2.1, 5.4) and rosuvastatin (aROR = 7.1; 2.6, 19.4) [p < 0.001 for all] but not for pravastatin and fluvastatin. We did not find any relationship between the occurrence of ED and the daily dose or the duration of exposure to statins (data not shown). Assessment of the association between drugs other than statins known to be at risk of ED confirmed a significant association for finasteride (aROR= 14.5; 95% CI 8.3, 25.4), fibrates (aROR=3.6; 2.6, 5.1), b-adrenergic receptor antagonists (aROR=1.5; 1.01, 2.1) and tricyclic antidepressants (aROR = 2.0; 1.2, 3.4) [all p<0.05].

Conclusion: Despite some methodological limitations, the present study suggests that statins may induce or worsen ED in accordance with other data. Further pharmacoepidemiological studies are necessary to confirm this conclusion and to improve the precision of the prevalence and/or the risk factors of this ADR.


Statin Simvastatin Atorvastatin Erectile Dysfunction Pravastatin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We are grateful for the helpful comments and assistance of Ms Jessica Yeung Shut-Yee, University of Texas Health Science Center, MD Anderson Cancer Center, Houston, TX, USA, who reviewed the draft versions of the manuscript. ## No funding was received for the preparation of this study. The authors have no conflicts of interest to declare.


  1. 1.
    Sweetman SC, editor. Martindale: the extra pharmacopoeia. 34th ed. London: Pharmaceutical Press, 2005Google Scholar
  2. 2.
    Walley T, Folino-Gallo P, Schwabe U, et al. Variations and increase in use of statins across Europe: data from administrative databases. EuroMedStat Group. BMJ 2004; 328: 385–6PubMedCrossRefGoogle Scholar
  3. 3.
    Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Study (4S). Lancet 1994; 344: 1383–9Google Scholar
  4. 4.
    Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004; 30: 803–7PubMedCrossRefGoogle Scholar
  5. 5.
    Halkin A, Lossos IS, Mevaorach D. HMG-CoA reductase inhibitor-induced impotence [letter]. Ann Pharmacother 1996; 30: 192PubMedGoogle Scholar
  6. 6.
    Schneider J, Kaffarnik H. Impotence in patients treated with clofibrate. Atherosclerosis 1975; 21: 455–7PubMedCrossRefGoogle Scholar
  7. 7.
    Pizzarro S, Bargay J, D’Agosto P. Gemfibrozil-induced impotence [letter]. Lancet 1990; 336: 1135CrossRefGoogle Scholar
  8. 8.
    Bharani A. Sexual dysfunction after gemfibrozil [letter]. BMJ 1992; 305: 693PubMedCrossRefGoogle Scholar
  9. 9.
    Figueras A, Castel JM, Laporte JR, et al. Gemfibrozil-induced impotence [letter]. Ann Pharmacother 1993; 27: 982PubMedGoogle Scholar
  10. 10.
    Caraval A, Macias D, Sainz M, et al. HMG CoA Reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. Drug Saf 2006; 2: 143–9CrossRefGoogle Scholar
  11. 11.
    Moore N, Noblet C, Kreft-Jais C, et al. French pharmaco-vigilance database system: examples of utilisation. Therapie 1995; 50: 557–62PubMedGoogle Scholar
  12. 12.
    Brown EG, Wood L, Wood S. The medical dictionary for regulatory authorities. Drug Saf 1999; 2: 109–17CrossRefGoogle Scholar
  13. 13.
    Moore N, Thiessard F, Begaud B. The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 2005; 14: 285–6PubMedCrossRefGoogle Scholar
  14. 14.
    Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483–6PubMedCrossRefGoogle Scholar
  15. 15.
    Bate A, Lindquist M, Edwards IR, et al. Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315–21PubMedCrossRefGoogle Scholar
  16. 16.
    van Puijenbroek EP, Bate A, Leufkens HGM, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 3–10PubMedCrossRefGoogle Scholar
  17. 17.
    Jackson G. Simvastatin and impotence. BMJ 1997; 315: 31CrossRefGoogle Scholar
  18. 18.
    Boyd IW. HMG-CoA reductase inhibitor-induced impotence [letter]. Ann Pharmacother 1996; 30: 1199PubMedGoogle Scholar
  19. 19.
    Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Prac 2002; 19: 95–8CrossRefGoogle Scholar
  20. 20.
    Adverse Drug Reactions Advisory Committee. Simvastatin and adverse endocrine effects in men. Aust Adverse Drug React Bull 1995; 14: 10Google Scholar
  21. 21.
    Hermann HC, Levine LA, Macaluso J, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med 2006; 2: 303–8CrossRefGoogle Scholar
  22. 22.
    Bank AJ, Kelly AS, Kaiser DR, et al. The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. Vasc Med 2006; 4: 251–7CrossRefGoogle Scholar
  23. 23.
    Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003; 89: 251–3PubMedCrossRefGoogle Scholar
  24. 24.
    Bruckert E, Giral P, Heshmati HM, et al. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 1996; 21: 89–94PubMedCrossRefGoogle Scholar
  25. 25.
    Lewis RW. Epidemiology of erectile dysfunction. Urol Clin North Am 2001; 28: 209–16, viiPubMedCrossRefGoogle Scholar
  26. 26.
    Berthet S, Grolleau S, Brefel-Courbon C, et al. Prevalence of diabetes in France and drug use: study based on the French Pharmacovigilance Database. Therapie 2007; 6: 483–8CrossRefGoogle Scholar
  27. 27.
    Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French Pharmacovigilance System Database. Br J Clin Pharmacol 1997; 44: 513–8PubMedCrossRefGoogle Scholar
  28. 28.
    Lugardon S, Lapeyre-Mestre M, Montastruc JL. Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (rofecoxib and celecoxib): a case/non-case study from the French Pharmacovigilance Database. Eur J Clin Pharmacol 2004; 9: 673–7CrossRefGoogle Scholar
  29. 29.
    Kaminetsky J. Epidemiology and pathophysiology of male sexual dysfunction. Int J Impot Res 2008; 20 Suppl. 1: S3–10PubMedCrossRefGoogle Scholar
  30. 30.
    de Graaf L, Brouwers AH, Diemont WL. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors? Br J Clin Pharmacol 2004; 3: 326–8CrossRefGoogle Scholar
  31. 31.
    Smals AG, Weusten JJ, Benraad TJ, et al. The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity. Steroid Biochem Mol Biol 1991; 38: 465–8CrossRefGoogle Scholar
  32. 32.
    Azzarito C, Boiardi L, Vergoni W, et al. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm Metab Res 1996; 28: 193–8PubMedCrossRefGoogle Scholar
  33. 33.
    Jay RH, Sturley RH, Stirling C, et al. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. Br J Clin Pharmacol 1991; 32: 417–22PubMedCrossRefGoogle Scholar
  34. 34.
    Solomon H, Samarasinghe YP, Feher MD, et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 2006; 60: 141–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Catherine Do
    • 1
    • 2
  • Eric Huyghe
    • 3
  • Maryse Lapeyre-Mestre
    • 1
  • Jean Louis Montastruc
    • 1
    • 2
  • Haleh Bagheri
    • 1
    • 2
    Email author
  1. 1.Facultéde Médecine PurpanUniversitéde Toulouse, UPS, Unitéde Pharmacoépidémiologie EA 3696ToulouseFrance
  2. 2.Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d’Informations sur le MédicamentCentre Hospitalier Universitaire de ToulouseToulouseFrance
  3. 3.Service d’Urologie et Andrologie, EA 3694UniversitéPaul Sabatier, Hôpital Paule de ViguierToulouseFrance

Personalised recommendations